+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiovascular Drugs Market Research Reports

From
Purinoceptor P2Y12 Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Purinoceptor P2Y12 Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Apolipoprotein C-III Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Apolipoprotein C-III Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
ACE/ARB Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

ACE/ARB Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Angiotensin Type 1 Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Angiotensin Type 1 Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Congenital Heart Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Heart Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Persistent Pulmonary Hypertension Of The Newborn - Pipeline Insight, 2025 - Product Thumbnail Image

Persistent Pulmonary Hypertension Of The Newborn - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hypercholesterolaemia - Pipeline Insight, 2025 - Product Thumbnail Image

Hypercholesterolaemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Cholesterol Absorption Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Cholesterol Absorption Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Beta-1 Receptors Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Beta-1 Receptors Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
PDE 1 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

PDE 1 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Beta-2 Receptors Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Beta-2 Receptors Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
From
Loading Indicator

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more